Latest Breaking News On - Will geist - Page 1 : comparemela.com

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Anaheim convention centerUnited statesDavid clairChris hegerSara carilloInvestor relations corporate developmentNational institute for bioprocessing researchBio techne corporationPrnewswire bio techne corporationProtein sciences segmentTechne corporationMass spectrometryAllied topicsProtein charge heterogeneity characterizationAnaheim conventionNational institute

ScaleReady announces $20 Million G-Rex® grant program for the advancement of cell and gene therapy (CGT) development and manufacturing

St. Paul, MN, May 29, 2024 – ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced the launch of the G-Rex® Grant Program, a $20 million initiative to propel the advancement of cell and gene-modified cell therapies (CGT). The G-Rex® Gran.

John wilsonFresenius kabiJosh ludwigWilson wolfProtein sciences at bio techne corporationBio techne corporationGrant programWilson wolf manufacturingGlobal commercial directorWill geistProtein sciencesTechne corporation

BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY S PROPRIETARY TECHNOLOGY

MINNEAPOLIS, May 22, 2024 /PRNewswire/ Bio-Techne Corporation and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines.

San diegoUnited statesBio techne exosomedxCris calsadaDavid clairSarah suttonBio techne corporationPrnewswire bio techne corporationRegulus therapeutics incProtein sciences segmentInvestor relations corporate developmentTechne corporationAutosomal dominant polycystic kidney diseaseSimple westernWill geistProtein sciences

BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY

MINNEAPOLIS, April 26, 2024 /PRNewswire/ Bio-Techne Corporation and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder , a first of.

Naren shettyNarayana nethralayaArkasubhra ghoshBio techne ellaDavid clairRohit shettyBio techne protein sciences segmentBio techne corporationNarayana nethralaya foundationInvestor relations corporate developmentBio marker pathfinderGrow laboratoriesDry eye diseaseDiabetic retinopathyWill geistProtein sciences

Bio-Techne to present at the KeyBanc Life Sciences & MedTech Investor Forum

Bio-Techne Corporation today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT.

Laura thomsonBio techne corporationProtein sciences segmentKeybanc life sciences medtech investor forum onFrom bio technemarTechne corporationWill geistKeybanc life sciencesMedtech investor forumInvestor relations